Anticoagulation with nafamostat mesilate during extracorporeal life support
- 16 July 2022
- journal article
- review article
- Published by Elsevier in International Journal of Cardiology
- Vol. 366, 71-79
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Nafamostat Mesilate for Anticoagulation in Continuous Renal Replacement TherapyThe International Journal of Artificial Organs, 2013
- Nafamostat Mesilate as an Anticoagulant during Continuous Veno-Venous Hemodialysis: A Three-Year Retrospective Cohort StudyThe International Journal of Artificial Organs, 2011
- Nafamostat Mesilate Attenuates Postreperfusion Syndrome during Liver TransplantationAmerican Journal of Transplantation, 2011
- Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shockThe Journal of Thoracic and Cardiovascular Surgery, 2010
- Plasma concentrations of inflammatory cytokines rise rapidly during ECMO-related SIRS due to the release of preformed stores in the intestineLaboratory Investigation, 2009
- Superior Outcome of Nafamostat Mesilate as an Anticoagulant in Patients Undergoing Maintenance Hemodialysis with Intracerebral HemorrhageRenal Failure, 2009
- Hematological Problems During the Use of Cardiac Assist Devices: Clinical Experiences in JapanArtificial Organs, 2008
- Clinical Results of Extracorporeal Membrane Oxygenation (ECMO) Support for Acute Respiratory Failure: A Comparison of a Centrifugal Pump ECMO with a Roller Pump ECMOSurgery Today, 2004
- Nafamostat mesilate suppresses NF-κB activation and NO overproduction in LPS-treated macrophagesInternational Immunopharmacology, 2003
- Ideal Anticoagulation for Use With a Left Ventricular Assist DeviceASAIO Journal, 1995